Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• Maternally expressed gene 3 (Meg3) is a long non-coding RNA implicated in tumorigenesis.
• Skp2 promotes cancer cell growth by degrading p27, a CDK inhibitor, particularly in non-small cell lung cancer (NSCLC).
• The regulatory relationship between Meg3 and Skp2 in NSCLC remains uncharacterized.

Purpose of the Study:

• To investigate the regulatory relationship between Meg3 and Skp2 in NSCLC.
• To elucidate the mechanism by which Meg3 influences Skp2 expression and function.
• To explore the potential cooperative roles of Meg3 and microRNAs in NSCLC pathogenesis.

Main Methods:

• Comparative analysis of Meg3 and Skp2 levels in NSCLC tissues versus non-tumor tissues.
• In vitro experiments involving Meg3 overexpression and depletion in NSCLC cells.
• Bioinformatic analysis and luciferase reporter assays to assess mRNA-protein interactions.
• Fluorescent in situ hybridization to determine co-localization of Meg3 and miR-3163.

Main Results:

• NSCLC tissues exhibit higher Skp2 and lower Meg3 levels compared to non-tumor tissues, with an inverse correlation.
• Meg3 overexpression reduces Skp2 protein and increases p27 protein in NSCLC cells, while Meg3 depletion has the opposite effect, without altering Skp2 mRNA levels.
• Bioinformatics and luciferase assays confirm that miR-3163 binds to Skp2 mRNA, inhibiting its translation.
• Meg3 enhances miR-3163's inhibitory effect on Skp2 translation, with both molecules co-localizing in NSCLC cells.

Conclusions:

• Meg3 regulates Skp2 protein levels post-transcriptionally in NSCLC.
• Meg3 and miR-3163 cooperate to suppress Skp2 mRNA translation in NSCLC cells.
• This coordinated suppression mechanism by Meg3 and miR-3163 inhibits NSCLC cell growth, suggesting a novel therapeutic strategy.